טוען...

Theranostics in immuno-oncology using nanobody derivatives

Targeted therapy and immunotherapy have become mainstream in cancer treatment. However, only patient subsets benefit from these expensive therapies, and often responses are short‐lived or coincide with side effects. A growing modality in precision oncology is the development of theranostics, as this...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Theranostics
Main Authors: Lecocq, Quentin, De Vlaeminck, Yannick, Hanssens, Heleen, D'Huyvetter, Matthias, Raes, Geert, Goyvaerts, Cleo, Keyaerts, Marleen, Devoogdt, Nick, Breckpot, Karine
פורמט: Artigo
שפה:Inglês
יצא לאור: Ivyspring International Publisher 2019
נושאים:
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC6831473/
https://ncbi.nlm.nih.gov/pubmed/31695800
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/thno.34941
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!